Morningstar research shows growing role for CROs and CDMOs

With demand for outsourcing continuing to increase, US financial services firm Morningstar has published a  report into the industry landscape, outlining the increasingly central role that the sector plays in drug and biologic development.

Major pharma and biotech companies have  for some time relied on contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) to assist with drug discovery, development and manufacturing.

This trend is set to continue, according to Morningstar’s research, which finds that substantial investments in biologics will “create a tailwind for the CRO and CDMO industry,” due to the complexity of these molecules.